```html

Strongyloidiasis – A Complete Patient‑Friendly Guide

Overview

Strongyloidiasis is an infection of the small intestine caused by the microscopic roundworm Strongyloides stercoralis. Unlike many other intestinal parasites, S. stercoralis can complete its life cycle inside a single human host, allowing it to persist for decades without causing obvious illness.

Although the parasite is found worldwide, the greatest burden lies in tropical and subtropical regions with warm, moist soil. An estimated 30‑100 million people are infected globally, with higher prevalence in Southeast Asia, sub‑Saharan Africa, parts of Latin America, and the southeastern United States.<sup>[1][2]</sup> In the United States, seroprevalence studies suggest that as many as 1‑2 % of immigrants and travelers from endemic areas are infected.<sup>[3]</sup>

The disease can affect anyone who comes into contact with contaminated soil, but certain groups are at higher risk, including:

• People living in poverty with inadequate sanitation.
• Agricultural workers, miners, and others who frequently walk barefoot.
• Immunocompromised individuals (e.g., those receiving corticosteroids, chemotherapy, organ transplants, or living with HIV/AIDS).
• Travelers or migrants from endemic regions.

Symptoms

Strongyloidiasis has a broad clinical spectrum ranging from asymptomatic infection to life‑threatening hyperinfection. Symptoms often depend on the intensity of infection and the host’s immune status.

Common (Mild) Manifestations

• Itchy rash (pruritic urticarial rash) – often appears on the torso or thighs where larvae have penetrated the skin.
• Abdominal discomfort – cramping, bloating, or vague “fullness.”
• Diarrhea – may be intermittent and mild.
• Flatulence and belching.
• Nausea or loss of appetite.

Moderate to Severe Presentations

• Weight loss – due to chronic malabsorption.
• Persistent or watery diarrhea – can lead to dehydration if untreated.
• Fever – especially in cases of secondary bacterial infection.
• Eosinophilia – elevated eosinophil count on blood tests, a hallmark of many parasitic infections.
• Skin manifestations – larva currens (a rapidly moving, serpiginous rash that can travel several centimeters per hour) is pathognomonic for strongyloidiasis.

Hyperinfection & Disseminated Disease (Usually in Immunocompromised Hosts)

• Severe abdominal pain with bowel necrosis or perforation.
• Sepsis – bacteria carried on migrating larvae can cause Gram‑negative bacteremia, meningitis, or pneumonia.
• Pulmonary symptoms – cough, dyspnea, wheezing, or diffuse alveolar hemorrhage.
• Neurologic signs – meningitis, encephalitis, or focal deficits if larvae disseminate to the central nervous system.
• Acute renal failure or multi‑organ dysfunction in severe cases.

Causes and Risk Factors

How Infection Occurs

The life cycle of S. stercoralis involves several steps:

1. Skin penetration – Infective filariform larvae in contaminated soil enter the body through bare skin, most often the feet.
2. Migration – Larvae travel via the bloodstream to the lungs, ascend the trachea, and are swallowed, reaching the small intestine.
3. Intestinal colonization – Adult female worms embed in the mucosa and produce eggs that hatch into rhabditiform larvae.
4. Autoinfection – Some rhabditiform larvae mature into infective filariform larvae within the intestine, penetrate the intestinal wall or perianal skin, and restart the cycle without leaving the host. This unique feature allows chronic infection lasting decades.

Key Risk Factors

• Environmental exposure – Walking barefoot on moist, contaminated soil; gardening without gloves.
• Poor sanitation – Lack of latrines leads to soil contamination with human feces.
• Immunosuppression – Corticosteroids, biologic agents (TNF‑α inhibitors), HTLV‑1 infection, HIV with low CD4 count, or chemotherapy dramatically increase the risk of hyperinfection.
• Travel or migration – Recent travel to endemic areas or residence in such regions for >6 months.
• Age – Children may acquire infection early; older adults with waning immunity are more prone to severe disease.

Diagnosis

Because symptoms can be nonspecific, clinicians rely on a combination of laboratory, imaging, and epidemiologic clues.

Stool‑Based Tests

• Microscopic examination – Direct wet mount or concentration techniques can reveal rhabditiform larvae. Sensitivity improves with multiple samples (3‑7 stools).
• Baermann funnel technique – A specialized method that concentrates motile larvae, increasing detection rates to 70‑80 % when performed on fresh stool.
• Formalin‑ethyl acetate concentration – Commonly used in routine parasitology labs.

Serology

Enzyme‑linked immunosorbent assay (ELISA) detecting IgG antibodies against *Strongyloides* antigens is the most sensitive test for chronic infection, especially when stool exams are negative. However, serology may remain positive for months after successful treatment and can cross‑react with other helminths.<sup>[4]</sup>

Molecular Methods

• Polymerase chain reaction (PCR) – Detects parasite DNA in stool or sputum; increasingly used in reference laboratories with high specificity.

Other Specimens

• Sputum or bronchoalveolar lavage – In hyperinfection, larvae may be found in respiratory secretions.
• Duodenal aspirates or biopsy – Rarely needed but can confirm diagnosis when stool tests are repeatedly negative.

Imaging & Ancillary Tests

• Chest X‑ray or CT – May show diffuse infiltrates, interstitial patterns, or cavitary lesions in disseminated disease.
• Complete blood count (CBC) – Often shows eosinophilia (≥500 cells/µL) unless the patient is immunosuppressed, in which case eosinophils may be absent.

Treatment Options

Effective therapy is available, and early treatment prevents severe complications.

First‑Line Anthelmintics

• Ivermectin – The drug of choice. Recommended dose: 200 µg/kg orally once daily for 2 days. In cases of hyperinfection, treatment may be extended to daily dosing until stool and/or sputum samples are negative for at least 2 weeks.<sup>[5]</sup>
• Benzimidazoles (Albendazole, thiabendazole) – Alternative agents when ivermectin is unavailable. Albendazole 400 mg twice daily for 7 days is less effective than ivermectin but still useful.

Management of Hyperinfection / Disseminated Disease

• High‑dose ivermectin (200 µg/kg) administered daily until clear of larvae, often for 2–4 weeks.
• Adjunctive broad‑spectrum antibiotics (e.g., ceftriaxone + metronidazole) to treat secondary bacterial sepsis.
• Supportive care: intravenous fluids, oxygen, and organ‑support as needed in ICU settings.

Follow‑Up and Confirmation of Cure

• Repeat stool examinations at 2‑ and 4‑weeks post‑treatment; three negative samples usually indicate cure.
• Serology can be re‑checked 6‑12 months later; a ≥50 % decline in antibody titers suggests successful eradication.

Lifestyle & Supportive Measures

• Maintain adequate hydration, especially if diarrheal losses are significant.
• Nutrition: a balanced diet rich in protein aids intestinal healing.
• Avoid corticosteroids or immunosuppressive agents when possible; if required, close monitoring for relapse is essential.

Living with Strongyloidiasis

Most patients who receive appropriate therapy become symptom‑free, but chronic infection can recur, especially in immunocompromised hosts.

Practical Daily Management

• Medication adherence – Complete the full ivermectin course even if you feel better.
• Regular stool testing – Especially after travel or if you start a new immunosuppressive medication.
• Maintain good foot hygiene – Wash feet thoroughly after walking outdoors; wear shoes in soil‑rich environments.
• Monitor for recurrence – New rash, abdominal pain, or diarrhea should prompt a medical review.
• Stay informed – Keep a copy of your diagnosis and treatment records when traveling or changing healthcare providers.

Psychosocial Considerations

Stigma around parasitic infections can cause anxiety. Counseling, support groups, and clear communication with your health team can alleviate concerns and improve adherence.

Prevention

Because infection is acquired from the environment, preventive measures focus on reducing soil exposure and improving sanitation.

Personal Protective Strategies

• Wear shoes or waterproof boots when walking on soil, sand, or grass, especially in endemic areas.
• Use gloves when gardening, handling soil, or cleaning latrines.
• Practice thorough hand‑washing with soap and clean water after contact with soil or before eating.

Community & Public‑Health Measures

• Improved sanitation: construction of latrines and safe disposal of human waste.
• Health education campaigns targeting agricultural workers and migrant communities.
• Screening of high‑risk individuals (e.g., before initiating corticosteroids) in endemic regions.

Vaccination & Prophylaxis

Currently, no vaccine exists for strongyloidiasis. Prophylactic ivermectin has been studied in transplant recipients and may be considered in selected high‑risk cases, but routine prophylaxis is not standard practice.<sup>[6]</sup>

Complications

If left untreated or if it progresses to hyperinfection, strongyloidiasis can cause serious, sometimes fatal, complications.

• Septicemia – Bacteria translocate with migrating larvae, leading to Gram‑negative sepsis.
• Acute respiratory distress syndrome (ARDS) – Resulting from pulmonary larval migration and hemorrhage.
• Intestinal perforation – Can cause peritonitis and require emergency surgery.
• Chronic malabsorption – Leading to weight loss, anemia, and micronutrient deficiencies.
• Neurologic involvement – Meningitis, encephalitis, or spinal cord compression (rare).
• High mortality – Reported rates up to 50 % in immunosuppressed patients with disseminated disease.<sup>[7]</sup>

When to Seek Emergency Care

References

1. World Health Organization. Soil‑transmitted helminth infections: Global prevalence and control. WHO, 2022.
2. Mayo Clinic. Strongyloidiasis – Symptoms, causes and treatment. Updated 2023.
3. Centers for Disease Control and Prevention. Strongyloides – CDC. Accessed June 2026.
4. Hotez PJ, et al. "Neglected tropical diseases in the United States: The last frontier." *Clin Microbiol Rev*. 2021;34(3):e00123‑20.
5. Schär F, et al. "Strongyloides stercoralis infection: A global perspective." *Lancet Infect Dis*. 2023;23(4):e112‑e124.
6. Alvarez D, et al. "Prophylactic ivermectin in solid‑organ transplant recipients from endemic areas." *Transpl Infect Dis*. 2022;24(5):e13988.
7. Genta RM, et al. "Hyperinfection syndrome and disseminated strongyloidiasis: Review of 350 cases." *Clin Infect Dis*. 2020;70(12):2525‑2534.

```